JSKN 016
Alternative Names: JSKN-016Latest Information Update: 18 Jul 2023
At a glance
- Originator Alphamab Oncology
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jul 2023 JSKN 016 is available for licensing as of 17 Jul 2023. https://www.alphamabonc.com/en/company/partnering.html (Alphamab Oncology Website, July 2023)
- 17 Jul 2023 Preclinical trials in Cancer in China (unspecified route) (Alphamab Oncology pipeline, July 2023)